Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
9.97
-0.32 (-3.11%)
Oct 10, 2025, 4:00 PM EDT - Market closed
Amneal Pharmaceuticals Revenue
Amneal Pharmaceuticals had revenue of $724.51M in the quarter ending June 30, 2025, with 3.24% growth. This brings the company's revenue in the last twelve months to $2.85B, up 9.81% year-over-year. In the year 2024, Amneal Pharmaceuticals had annual revenue of $2.79B with 16.73% growth.
Revenue (ttm)
$2.85B
Revenue Growth
+9.81%
P/S Ratio
1.09
Revenue / Employee
$343,725
Employees
8,300
Market Cap
3.13B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.79B | 400.35M | 16.73% |
| Dec 31, 2023 | 2.39B | 181.30M | 8.20% |
| Dec 31, 2022 | 2.21B | 118.64M | 5.67% |
| Dec 31, 2021 | 2.09B | 101.15M | 5.08% |
| Dec 31, 2020 | 1.99B | 366.15M | 22.51% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
AMRX News
- 12 days ago - Amneal to Report Third Quarter 2025 Results on October 30, 2025 - GlobeNewsWire
- 17 days ago - Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab) - GlobeNewsWire
- 20 days ago - Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01% - GlobeNewsWire
- 4 weeks ago - Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution - GlobeNewsWire
- 4 weeks ago - Amneal Pharmaceuticals: A Large, Diversified Clinical Portfolio That Keeps Growing - Seeking Alpha
- 5 weeks ago - Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension - GlobeNewsWire
- 2 months ago - Amneal Pharmaceuticals, Inc. (AMRX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Knight Therapeutics Announces Regulatory Submission of CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Mexico - GlobeNewsWire